Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

AMPK pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (22) Akt (2) Amyloid-β (1) Apoptosis (12) Aurora Kinase (2) Autophagy (11) Bacterial (1) Bcl-2 Family (2) Beta-secretase (2) Caspase (2) Cholinesterase (ChE) (2) EGFR (1) Endogenous Metabolite (1) ERK (1) FLT3 (1) HDAC (2) Keap1-Nrf2 (3) Mitochondrial Metabolism (1) mTOR (2) NF-κB (2) NO Synthase (2) Organoid (1) p38 MAPK (1) Parasite (1) PARP (1) Phosphatase (1) PKA (1) PKC (1) Reactive Oxygen Species (4) Sirtuin (1) STAT (1) TGF-β Receptor (1) Tyrosinase (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (9) Metabolic Disease (17) Neurological Disease (5)

By Targets:

AMPK (22)

Akt (2)

Amyloid-β (1)

Apoptosis (12)

Aurora Kinase (2)

Autophagy (11)

Bacterial (1)

Bcl-2 Family (2)

Beta-secretase (2)

Caspase (2)

Cholinesterase (ChE) (2)

EGFR (1)

Endogenous Metabolite (1)

ERK (1)

FLT3 (1)

HDAC (2)

Keap1-Nrf2 (3)

Mitochondrial Metabolism (1)

mTOR (2)

NF-κB (2)

NO Synthase (2)

Organoid (1)

p38 MAPK (1)

Parasite (1)

PARP (1)

Phosphatase (1)

PKA (1)

PKC (1)

Reactive Oxygen Species (4)

Sirtuin (1)

STAT (1)

TGF-β Receptor (1)

Tyrosinase (1)

By Research Areas:

Cancer (23)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (17)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: AMPK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155363

AMPK activator 13	AMPK	Metabolic Disease
AMPK activator 13 is a potent activator of *AMPK. AMPK* activator 13 inhibits mitotic clonal expansion of 3T3-L1 cells by activating AMPK pathway and enhances cell mitochondrial oxygen consumption rate. AMPK activator 13 can be used in study obesity .

HY-112108

Chitosan oligosaccharide 4 Publications Verification COS	AMPK Endogenous Metabolite	Metabolic Disease Cancer
Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates *AMPK* and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.

HY-130723A

AMPK activator 2 hydrochloride	AMPK	Cancer
AMPK activator 2 (compound 7a) hydrochloride, a fluorine-containing proguanil derivative, up-regulates *AMPK* signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 hydrochloride inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .

HY-130723

AMPK activator 2	AMPK	Cancer
AMPK activator 2 (compound 7a), a fluorine-containing proguanil derivative, up-regulates *AMPK* signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-N2312

Mogrol 1 Publications Verification	ERK STAT	Cancer
Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating *AMPK* signaling.

HY-153886

Wu-5

FLT3 AMPK Apoptosis Cancer

Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis .

Wu-5	FLT3 AMPK Apoptosis	Cancer
Wu-5 is a USP10 inhibitor that can inhibit FLT3 and *AMPK* pathways, induce FLT3-ITD degradation and induce apoptosis .

HY-N4176

Ginkgolide K	Autophagy	Neurological Disease
Ginkgolide K, isolated from Ginkgo biloba, induces protective autophagy through the AMPK/mTOR/ULK1 signaling pathway. Ginkgolide K possesses neuroprotective activity .

HY-N1411

Platycodin D 4 Publications Verification
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .

HY-N10093

Chamaejasmine Chamaejasmin	Apoptosis AMPK Autophagy Reactive Oxygen Species	Cancer
Chamaejasmine is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L. Chamaejasmine has antitumor activity. Chamaejasmine induces cell apoptosis, autophagy and ROS production, and activates the activity of *AMPK/mTOR* signal pathway .

HY-W017212

Methyl cinnamate Methyl 3-phenylpropenoate	Tyrosinase Bacterial AMPK	Infection Metabolic Disease
Methyl cinnamate (Methyl 3-phenylpropenoate), an active component of Zanthoxylum armatum, is a widely used natural flavor compound. Methyl cinnamate (Methyl 3-phenylpropenoate) possesses antimicrobial activity and is a tyrosinase inhibitor that can prevent food browning. Methyl cinnamate (Methyl 3-phenylpropenoate) has antiadipogenic activity through mechanisms mediated, in part, by the *CaMKK2-AMPK* signaling pathway .

HY-N4253

Kudinoside D	Others	Metabolic Disease
Kudinoside D is a main natural component of triterpenoid saponin derived from Ilex kudingcha. Kudinoside D suppresses adipogenesis through modulation of the AMPK pathway in 3T3-L1 adipocytes .

HY-N1419

Vaccarin
Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway .

HY-N0072

Brazilin	Apoptosis Autophagy	Inflammation/Immunology Cancer
Brazilin is a red dye precursor obtained from the heartwood of several species of tropical hardwoods. Brazilin inhibits the cells proliferation, promotes apoptosis, and induces autophagy through the AMPK/mTOR pathway. Brazilin shows chondroprotective and anti-inflammatory activities .

HY-N0735

Phellodendrine chloride	Autophagy	Cancer
Phellodendrine chloride is a plant alkaloid found in Phellodendron amurense. Phellodendrine chloride suppresses the proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis . Phellodendrine chloride promotes autophagy by regulating the AMPK/mTOR pathway and reduce the intestinal damage of ulcerative colitis .

HY-N6904

Crocetin monomethyl ester	Amyloid-β	Neurological Disease Inflammation/Immunology
Crocetin monomethyl ester, isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity . Crocetin monomethyl ester promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated *AMPK* pathway .

HY-N0592

Demethyleneberberine	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a *AMPK* activator for treating non-alcoholic fatty liver disease (NAFLD) .

HY-125355

SEC	Apoptosis	Cancer
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation .

HY-N3426

Kazinol B	NO Synthase Akt AMPK	Metabolic Disease
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .

HY-N0592A

Demethyleneberberine chloride	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine chloride is a natural mitochondria-targeted antioxidant. Demethyleneberberine chloride alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine chloride could serve as a *AMPK* activator for researching non-alcoholic fatty liver disease (NAFLD) .

HY-13418

Dorsomorphin dihydrochloride Maximum Cited Publications 438 Publications Verification Compound C dihydrochloride; BML-275 dihydrochloride	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive *AMPK* inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-163315

YPLP	Keap1-Nrf2 AMPK	Metabolic Disease
YPLP is a yeast-derived peptide Tyr-Pro-Leu-Pro, which exhibits activity in anti fatigue mechanisms through the nuclear factor erythroid-2-related factor 2 (Nrf2)- and AMP-activated protein kinase (AMPK) pathway. YPLP is orally active .

HY-N0404

Sinigrin 1 Publications Verification	p38 MAPK AMPK	Metabolic Disease Inflammation/Immunology
Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the *AMPK* and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects .

HY-119137

AMDE-1	Autophagy AMPK	Cancer
AMDE-1 is a potent autophagy inducer. AMDE-1 induces autophagy by the AMPK-mTORC1-ULK1 pathway and at the same time inhibited autophagy-mediated degradation by causing lysosome dysfunction. AMDE-1 can be used in research of cancer .

HY-N7676

Marein	AMPK HDAC	Cardiovascular Disease Neurological Disease Metabolic Disease
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the **AMPK signal pathway*. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC* inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct *AMPK* activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects .

HY-16397

Phenformin Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis	Metabolic Disease Cancer
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .

HY-133556

IQZ23	AMPK	Metabolic Disease
IQZ23 inhibits adipocyte differentiation via *AMPK* pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC₅₀=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the *AKT/mTOR/AMPK/p38* pathway in leukemic cells. Antitumor activity .

HY-143656

SH379	Autophagy	Endocrinology
SH379 is the derivative of 2-methylpyrimidine-fused tricyclic diterpene. SH379 is a potent and orally active anti-late-onset hypogonadism agent. SH379 significantly promotes the expression of the key testosterone synthesis-related enzymes StAR and 3β-HSD. SH379 stimulates autophagy through regulating AMPK/mTOR signaling pathway .

HY-118160

PPM-18 NSC 73233	NO Synthase	Inflammation/Immunology Cancer
PPM-18 (NSC 73233), a potent anti-inflammatory agent, inhibits nitric oxide synthase expression. PPM-18 is a potent inhibitor of iNOS expression by blocking the binding of NF-κB to promoter . PPM-18, an analog of Vitamin K, induces autophagy and apoptosis in bladder cancer cells through ROS and AMPK signaling pathways .

HY-10971

Alisertib 35+ Cited Publications MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the *AKT/mTOR/AMPK/p38* pathway in leukemic cells. Antitumor activity .

HY-N12386

SIRT1 activator 1	Sirtuin	Cancer
SIRT1 activator 1(compound 3) is a derivative of marine compound xyloallenoide A isolated from the mangrove fungus Xylaria sp.SIRT1 activator 1 shows angiogenic activities in zebrafish. SIRT1 activator 1 protects hEPC against AngII-induced senescence by increasing SIRT1 expression levels and balancing the AMPK/Akt signaling pathway .

HY-119678

Fortunellin	AMPK Keap1-Nrf2	Cardiovascular Disease Metabolic Disease
Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing *AMPK/Nrf2* pathway. Fortunellin can be used for diabetic cardiomyopathy research .

HY-124896

Bonannione A 6-Geranylnaringenin; Mimulone	Phosphatase Apoptosis Autophagy	Inflammation/Immunology Cancer
Bonannione A (6-Geranylnaringenin; Mimulone), a prenylflavonoid, is an orally active and potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 14 µM. Bonannione A triggers caspase-dependent apoptosis. Bonannione A induces autophagy through p53-mediated AMPK/mTOR pathway. Bonannione A shows anti-inflammatory, antiradical and anti-cancer activity .

HY-13755

Sulforaphane 30+ Cited Publications	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species	Inflammation/Immunology Cancer
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-N2447

Amarogentin 2 Publications Verification	AMPK Apoptosis	Metabolic Disease Cancer
Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating *AMPK* .

HY-N0226

Epiberberine	Cholinesterase (ChE) Beta-secretase	Neurological Disease Metabolic Disease
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N0226A

Epiberberine chloride 3 Publications Verification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species	Neurological Disease Metabolic Disease
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N0281

Daphnetin 2 Publications Verification 7,8-Dihydroxycoumarin	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite	Inflammation/Immunology Cancer
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1ß, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	740 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

740 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

HY-L015

PI3K/Akt/mTOR Compound Library	568 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 568 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PI3K/Akt/mTOR Compound Library

568 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 568 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

YPLP	Keap1-Nrf2 AMPK	Metabolic Disease
YPLP is a yeast-derived peptide Tyr-Pro-Leu-Pro, which exhibits activity in anti fatigue mechanisms through the nuclear factor erythroid-2-related factor 2 (Nrf2)- and AMP-activated protein kinase (AMPK) pathway. YPLP is orally active .

LKBtide	Peptides	Others
LKBtide is a biological active peptide. (This is a peptide substrate that is phosphorylated by Serine/Threonine kinase 11 (STK11), also known as LKB1. LKBtide is derived from sucrose non-fermenting 1 (SNF1) protein kinase, which is normally activated by the LKB1/AMP-activated protein kinase (AMPK) signaling pathway.)

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks